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Abstract
Background: Hepatorenal tyrosinaemia (Tyr 1) is a rare inborn error of tyrosine metabolism. Without treatment,
patients are at high risk of developing acute liver failure, renal dysfunction and in the long run hepatocellular
carcinoma. The aim of our study was to collect cross-sectional data.
Methods: Via questionnaires we collected retrospective data of 168 patients with Tyr 1 from 21 centres (Europe,
Turkey and Israel) about diagnosis, treatment, monitoring and outcome. In a subsequent consensus workshop, we
discussed data and clinical implications.
Results: Early treatment by NTBC accompanied by diet is essential to prevent serious complications such as liver
failure, hepatocellular carcinoma and renal disease. As patients may remain initially asymptomatic or develop
uncharacteristic clinical symptoms in the first months of life newborn mass screening using succinylacetone (SA)
as a screening parameter in dried blood is mandatory for early diagnosis. NTBC-treatment has to be combined
with natural protein restriction supplemented with essential amino acids. NTBC dosage should be reduced to the
minimal dose allowing metabolic control, once daily dosing may be an option in older children and adults in
order to increase compliance. Metabolic control is judged by SA (below detection limit) in dried blood or urine,
plasma tyrosine (<400 μM) and NTBC-levels in the therapeutic range (20–40 μM). Side effects of NTBC are mild
and often transient.
Indications for liver transplantation are hepatocellular carcinoma or failure to respond to NTBC. Follow-up procedures
should include liver and kidney function tests, tumor markers and imaging, ophthalmological examination, blood
count, psychomotor and intelligence testing as well as therapeutic monitoring (SA, tyrosine, NTBC in blood).
Conclusion: Based on the data from 21 centres treating 168 patients we were able to characterize current practice
and clinical experience in Tyr 1. This information could form the basis for clinical practice recommendations,
however further prospective data are required to underpin some of the recommendations.
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Background
Hepatorenal tyrosinaemia or tyrosinaemia type 1 (Tyr 1)
is a rare autosomal-recessive disorder of tyrosine metab-
olism with an incidence of 1:125,000 in central Europe.
It is more frequent in other regions like Turkey, Quebec
and India.
In Tyr 1, the deficiency of the enzyme fumarylacetoa-
cetase causes an accumulation of tyrosine and toxic
metabolites (Figure 1) [1]. Tyr 1 mainly affects liver and
kidney function, porphyria-like neurological crisis and
cardiomyopathy are less frequently observed [2]. Hepa-
tocellular carcinoma is a known long-term complication
[3,4]. Recently, psychomotor impairment has been ob-
served in a number of patients [5-8].
Diagnosis is based on the elevated levels of succinylace-
tone (SA) in urine and/or blood, which is a pathogno-
monic finding in Tyr 1. Mutation analysis as a diagnostic
tool is not routinely performed, except in cases where pre-
natal diagnosis is planned [9].
The state of the art treatment in Tyr 1 consists of
two principles: inhibition of the formation of toxic
metabolites by [2-(2-nitro-4-trifluoromethylbenzoyl)-1,
3-cyclohexanedione; nitisinone] NTBC and reduction
of tyrosine levels by dietary treatment (Figure 1). SA
as a surrogate parameter of toxicity is commonly used
for therapeutic monitoring [10].
Despite considerable progress in the diagnosis and man-
agement of patients with Tyr 1 in the last 20 years there is
lack of a guideline. A review of the literature revealed only
few regional studies [11-17]. The aim of our study was to
collect retrospective cross-sectional data from an inter-
national group of physicians treating patients with Tyr 1
in Europe, Turkey and Israel. We sent questionnaires re-
garding diagnostic procedures, treatment and monitoring
of therapy in Tyr 1-patients to metabolic centres treating
patients with Tyr 1. Some of the experts later met for a
workshop to discuss the findings and possible implications
for practical medicine. In order to avoid unintended bias
and to stimulate discussion we invited colleagues not dir-
ectly involved in the clinical management of Tyr 1 (adult
hepatologist, geneticist, pharmacologist, screening expert)
to attend our expert meeting.
Patients would benefit from a standardized protocol
for diagnosis, treatment and monitoring, which would
also decrease disparities in health care delivery among
different geographical regions and promote reimburse-
ment for drugs, dietary products and therapeutic moni-
toring by insurance companies.
Recently, recommendations based on personal opin-
ions and experiences from a group of expert clinicians
were published [18]. Obviously, randomized multi-centre,
placebo-controlled, double blind studies are not possible
in inborn errors of metabolism due to their rarity. How-
ever, this drawback should not discourage creation of clin-
ical practice recommendations in this group of diseases.
As already pointed out by Vockley and coworkers [19,20]
clinical practice recommendations/guidelines may be de-
rived from the integration of evidence-based medicine,
Figure 1 Tyrosine metabolism.
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review of the literature and consensus from an inter-
national expert group.
As only regional studies in Tyr 1 have been published
in the past, data from a larger international cohort are
urgently required to proceed towards clinical practice
recommendations. This prompted us to collect cross-
sectional data on diagnosis, management, monitoring
and outcome of Tyr 1 in an international cohort.
Methods
Workshop participants and data collection
22 metabolic centres from Europe, Turkey and Israel par-
ticipated in this international survey, 21 centres contrib-
uted individual patient data. By this regional limitation we
hoped to facilitate the consensus process without falling
short of patients.
In preparation for the workshop, we sent question-
naires to the participating centres. Questionnaires con-
sisted of two parts: A general part on basic information
and principles of treatment in the single centres and a
second part on diagnosis, treatment, monitoring, and out-
come in each individual patient. Data from 168 patients
could be collected.
Results were presented and discussed during a 2 day
workshop in Hannover in November 2012. 21 paediatri-
cians from 12 countries who contributed data participated
in the workshop. To assist and stimulate discussions a
metabolic dietician (UM), a geneticist (SM), a pharma-
cologist (JJ), a screening specialist (JS) and 2 hepatologists
(AV, JE) specialized in the pathogenesis of HCC comple-
mented the group.
The study was approved by our local ethics review
board.
Outline of the questionnaire
The general part of the questionnaire contained ques-
tions on number and age range of patients, staff and fre-
quency of outpatient visits in the single centres.
Centres were asked to name and specify the tools used
for the diagnosis of Tyr 1-patients. Furthermore, they
were asked to supply data on dietary and medical treat-
ment as well as liver transplantation. This included data
on supplementation of vitamins and micronutrients, ini-
tial/total daily maintenance dose of NTBC, number of
and indication for liver transplantation. In this part of
the survey, general information on therapeutic monitor-
ing such as measurement of amino acids, succinylace-
tone, delta-aminolevulinate and NTBC was collected.
Moreover, centres were asked to outline their follow-up
procedures such as laboratory tests, imaging, psycho-
motor/neurological assessment and skeletal as well as
ocular examination. The participants had the opportunity
to give information on refund of expenses for NTBC,
tyrosine-free amino acid mixtures and low-protein food.
The second part of the questionnaire consisted of ques-
tions on each individual patient.
This part was divided into:
– demographic data
– diagnosis and clinical presentation
– initial laboratory findings and imaging
– drugs and diet
– NTBC side effects
– monitoring and follow-up
– clinical outcome
Demographic data
Centres were asked to supply data on the year of birth,
sex, current body weight and length, consanguinity, af-
fected family members, ethnic background, schooling
(normal or special education) and concomitant diseases.
Diagnosis and clinical presentation
We asked for the age at diagnosis of each single patient
and for specification of diagnostic tools used for new-
born screening or selective screening. Participants were
asked to itemize initial symptoms and to supply data on
mutation analysis of each single patient.
Initial laboratory findings and imaging
In this part, initial values of AFP/CEA, PT/ PTT, AST/
ALT/GGT, plasma phenylalanine/methionine/tyrosine and
SA were compiled. Furthermore, centres were asked to
specify results of initial imaging.
Drugs and diet
We asked for information on dosage of NTBC at differ-
ent age bands, number of doses per day and cumulative
years of NTBC-treatment. Supply of amino acid mix-
tures and total protein supply were also subject of this
part. Tyrosine and phenylalanine restriction and dietary
compliance were specifically addressed.
NTBC side effects
Participants were encouraged to report and specify any
side effect caused by NTBC.
Monitoring and follow-up
Centres supplied data on frequency and methods of liver
and kidney imaging, ophthalmological, cardiac, neuro-
logical and skeletal examination. The frequency of
outpatient-visits, developmental testing and dietitian
visits per year were specified.
Laboratory monitoring
We asked for data on the frequency of laboratory monitor-
ing and range of target levels for tyrosine, alfa-fetoprotein,
SA and delta- aminolevulinate.
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Participants specified the frequency and target values
of NTBC- levels (plasma/dried blood spots).
Clinical outcome
Centres were asked for clinical sequelae and onset in
each single patient.
If patients underwent liver transplantation, the partici-
pants were asked to supply data on indication, age, post-
transplant tyrosine, SA and alfa-fetoprotein levels and
complications.
Statistical analysis
Statistical analysis was performed using SPSS version 20
and 21. Descriptive analysis of data was carried out.
Analysis of age-dependency of symptoms and effects of
early NTBC- treatment on outcome was performed
using Pearson’s chi-squared test, if expected frequency
was below 5 (20%) Fisher’s exact test was used. Odds ra-
tio and confidence intervals were calculated. Normally
distributed laboratory values were analyzed with ANOVA
otherwise Kruskal-Wallis–test and Mann–Whitney-U-test
were performed.
Results
Centres
21 centres sent data from individual patients. On average
7 patients (range: 1–20) were followed per centre. Dieti-
tians were present in all centres, psychologists in 14/21
centres.
Demographic data
168 patients with Tyr 1 from 21 centres were included.
100 patients were males and 68 females. Patients were
aged between 0 and 24 years. The average follow-up
period was 9.1+/− 6.3 years.
Consanguinity was reported in 49/168 cases and af-
fected family members were found in 56/168 cases. 91 pa-
tients visited a mainstream school while 20/168 required
special education.
Diagnosis and clinical presentation
The average age at diagnosis was 12.9 months (SD: +/−
23.8, range: 0–183 months) for the whole group,
0.58 months (SD:+/−0.73, range 0–3 months) in patients
diagnosed via NBS and 15.5 months (SD:+/−24.9, range
0–183 months) in those diagnosed via selective screening.
Prenatal diagnosis was performed in 3/168 cases. 28/
168 cases were diagnosed via NBS (Figure 2). 1/28 pa-
tient presented symptoms before or at diagnosis and
suffered from renal dysfunction (nephromegaly, renal
tubular dysfunction, nephrocalcinosis) at the age of 12 days.
To our knowledge there were no false negative results
when SA was used as a screening parameter. Only few pa-
tients diagnosed via NBS developed clinical symptoms after
the start of therapy.
132 patients were diagnosed via selective screening.
The screening parameter in these patients was SA (112/
132 cases), mostly measured in urine. Data on initial
symptoms were present in 118/ 132 patients. 4/118 chil-
dren were selectively diagnosed because of an affected
sibling and showed no clinical symptoms. Further details
on diagnostic tools can be found in Figure 2.
114/168 patients developed symptoms. 40 patients
had only one single symptom at diagnosis, mostly
acute liver failure or liver dysfunction with bleeding
tendencies and elevated liver enzymes (Table 1). 74
symptomatic patients showed a combination of symp-
toms, mainly liver dysfunction combined with renal
dysfunction, in some cases combined with rickets. The
remaining cases had unspecific symptoms such as
fever, diarrhea, infections and feeding problems at
diagnosis.
Mutation analysis was performed in 58/168 patients.
The most frequent mutations were c.1062 + 5G > A
(IVS12 + 5G > A) homozygous (11 patients) and c. 554-
1G > T homozygous (13 patients). Using a retrospective
study-design we could not find a genotype-phenotype
correlation (both classifications of phenotype according
to Halvorsen 1990 as well as according to van Spronsen
1994 were tested separately).
Figure 2 Distribution of patients according to diagnostic procedure.
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Age-dependency of initial symptoms
Patients diagnosed via selective screening were less fre-
quently symptomatic during the first months of life com-
pared to older patients. Renal tubular dysfunction was
more frequently found in patients between 2–6 months of
age (35% affected; p = 0.007 vs < 2 months) and children
beyond 6 months (31%; p = 0.013 vs < 2 months) com-
pared to patients who were younger than 2 months (9%).
Nephromegaly, rickets, growth retardation and liver cir-
rhosis were more often observed in patients beyond
6 months of age, who also developed more frequently
HCC (13% affected; p = 0.047 vs < 2 months) compared
to patients younger than 2 months at diagnosis (0%)
(Figure 3b-f ).
Hepatomegaly did not show any age-dependency.
The number of patients suffering from acute liver fail-
ure was significantly higher in the group of patients
between 2–6 months of age (51% affected; p = 0.002
vs < 2 months) compared to those who were younger
(17%) or older (33%).
A combination of symptoms was found in 55% of
patients aged between 2–6 months (p < 0.001 vs <
2 months) and in 70% of patients older than six months
(p < 0.001), whereas a smaller number was observed in
the group of patients below 2 months of age.
Laboratory parameters at diagnosis and imaging
Parameters of liver function were generally normal in pa-
tients diagnosed via NBS or when prenatal diagnosis was
performed, whereas liver dysfunction frequently occurred
in patients detected by selective screening (Table 2).
The mean value of initial AFP in patients diagnosed via
NBS was 277,107 μg/l (+/− SD: 200,449 μg/l, median:
318,309 μg/l; range: 20–587,000 μg/l). Patients < 6 months
diagnosed via selective screening had initially a mean
AFP value of 136,516 (+/− SD: 124,792 μg/l; median:
109,302 μg/l; range: 100–576,626 μg/l). Patients diagnosed
beyond the age of 6 months, initially presented a mean
AFP level of 41,487 μg/l ( +/− SD: 58,368 μg/l; median:
16,210 μg/l; range: 34–265,140 μg/l).
At diagnosis, initial liver imaging was performed in
79% of cases (110 selectively screened patients, 16 pa-
tients diagnosed via NBS, 3 patients with prenatal diag-
nosis, 3 patients with no data on diagnosis); all patients
were examined by ultrasound of the liver. 19% of pa-
tients received a CT- and 24% MRI-scan in addition.
Abnormalities in liver imaging were detected in 99/132
(75%) of patients, mostly nodules and cirrhosis (50%);
3% presented with carcinoma (age range 6–14 months);
6% of patients showed nephromegaly; in 21% increased
echogenity was found. Only 4 patients diagnosed by
newborn screening had abnormal liver imaging.
Medication and diet
Data on NTBC treatment were obtained from 154/168
patients, 10/168 patients did not receive NTBC treat-
ment; 6/10 patients were born before 1992 (i.e. before
NTBC became routinely available), in 4/10 patients rea-
sons are unknown. In 4/168 patients no data on treat-
ment were available. Mean initial NTBC dosage was
1.7 mg/kg body weight (BW) per day (+/− SD: 0.5; range:
0.2-5 mg/kg BW per day). The number of cumulative
years on NTBC treatment was 7.6 years +/− 5.1 years
(range: 0–20 years) on average. In total 1157 NTBC years
were observed. The dose decreased with age; during the
first year of life the mean dose was 1.2 mg/kg BW per day
(+/− SD: 0.3, range: 0.7-2); decreasing to 1.1 mg/kg BW
per day (+/− SD: 0.3, range: 0.3-2.0 mg/kg BW per day)
during the age interval 1–6 years. The dose at age 6–10
years showed a mean value of 1.0 mg/kg BW per day (+/−
SD: 0.3, range: 0.05-2.6 mg/kg BW per day) and finally
a slight decrease to 0.91 mg/kg BW per day (range:
0.2-2.6 mg/kg BW per day) after the age of ten years
was found.
The current maintenance therapy was 1.0 mg/kg BW
per day (SD +/− 0.3; range: 0.3-2). The daily dose was
given in 1–3 doses per day, on average patients received
2 daily doses. NTBC-levels were monitored in 105 pa-
tients in plasma and in 46 patients in dried blood spots.
All patients tolerated NTBC without severe side effects.
Some cases with transient side effects were reported
(Table 3). Patients with side effects had NTBC levels be-
tween 32.3 to 71.1 μmol/l while NTBC levels in patients
without side effects ranged from 31.3 to 58.4 μmol/l.
Patients who were diagnosed and treated early (neo-
natal period) showed a lower rate of complications
(Figure 4a-g), especially HCC (analysis was performed
in 148 patients where age at NTBC start and clinical
course were known). Delayed NTBC- treatment was as-
sociated with an increased risk of liver carcinoma and
requirement of LTx. Treatment start within the age range
of 1–6 months resulted in a 2.5-fold risk of developing
Table 1 Patients with a single symptom at diagnosis
(100%= 40patients)
Symptom Patients (n) %
Acute liver failure 17 42.5
Liver dysfunction: bleeding tendencies,
elevated liver enzymes
7 17.5
Hepatomegaly 2 5.0
Cirrhosis 5 12.5
Nephromegaly 1 2.5
Renal tubular dysfunction 1 2.5
Growth retardation 3 7.5
Rickets 1 2.5
Renal dysfunction 3 7.5
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Figure 3 Initial symptoms are age-dependent. a-i: Age-dependency of initial symptoms: The most common symptoms like renal tubular
dysfunction, nephromegaly, growth retardation, rickets, liver dysfunction and carcinoma and the combination of symptoms are depicted.
*significant difference (p <0.05) vs < 2 months. n: <2 m =34 patients, 2-6 m = 43 patients, >6 m =61 patients.
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liver tumors with requirement of LTx compared to pa-
tients with treatment start in the neonatal period. Patients
aged between 7–12 months at start of NTBC treatment
showed a 6-fold risk whereas children beyond 12 months
of age had a 13-fold risk of tumor formation compared to
the group of patients treated before the age of 1 month.
Patients who received treatment beyond 6 months of age
had a 5-fold risk of developing renal dysfunction. Table 4
summarizes the odds ratios for different clinical sequelae
depending on the age at start of NTBC-treatment com-
pared to start of treatment in the neonatal period. When
NTBC treatment was initiated in the newborn period few
clinical sequelae were observed: psychomotor impairment
(7/28), ADHS and behavioral disorders (3/28), neuro-
logical crisis and learning difficulties (2/28), 1 patient suf-
fered from convulsions which were unrelated to HT1
based on family history. Mild hepatomegaly (4/28), cirrho-
sis (1/28), nephromegaly (1/28), renal tubular dysfunction
(1/28) were reported. Compliance with medication was
not addressed in the questionnaire.
In addition to NTBC administration, all patients re-
ceived dietary treatment. 16 centres added micronutrients
to the diet and supplemented vitamins. 38% of centres
treated their patients either with natural protein restric-
tion or calculated phenylalanine and tyrosine intake. 19%
of centres restricted either natural protein intake or calcu-
lated tyrosine intake. 19% treated their patients with nat-
ural protein restriction only and 24% of centres stated to
exclusively use restriction of phenylalanine and tyrosine
(Figure 5). Tyrosine restriction/calculation was done in
some centres in younger patients during the first year of
life whereas diet was more relaxed in older patients.
The total protein intake decreased with age. Patients
aged between 0–12 months at diagnosis had an initial
natural protein intake of 1.4 g/kg per day (+/− SD: 0.79)
supplemented with 1.2 g/kg per day via amino acid mix-
ture. Further values can be found in Table 5.
Liver transplantation
29/168 patients underwent liver transplantation; main
indication was hepatocellular carcinoma (72%), liver cir-
rhosis and liver failure were other sequelae necessitating
liver transplantation. The mean age was 80.5 months
(+/− SD: 64.5; range:7–252).
Four patients showed posttransplant morbidity, but
did not have to undergo retransplantation. Five cases
(21%) suffered from complications after liver transplant-
ation and underwent re-transplantation due to failure of
the transplanted liver. 2/5 patients died after retrans-
plantation; 3/5 died despite re-retransplantation.
Post-transplant tyrosine levels were: mean 198 μmol/l
(range: 17–756 μmol/l; normal: >1 month of age 28–
153 μmol/l); AFP levels: mean 6.7 μg/l (range: 0.9-27.7
μg/l, normal: <7 μg/l). After transplantation, additional
NTBC- treatment was given to 6 patients from 3 different
centres. 4 of them received a restriction of total protein.
Clinical sequelae
The most frequent complications in NTBC treated pa-
tients during the clinical course were impaired psycho-
motor development, hepatomegaly and cirrhosis (Table 6).
Table 2 Initial laboratory findings of liver function (mean values)-a comparison between early screened and late
diagnosed patients
≤ 6 months of age > 6 months of age Patients diagnosed via NBS
PTT 80.5 seconds (SD: +/−40.6; median: 66.7;
range: 39–181)
49.8 seconds (SD: +/−16.1; median: 51;
range: 13.3-89.4)
84.4 seconds (SD: +/−39.1; median: 77.2;
range: 45–168)
AST 113.3 U/l (SD: +/−116.7; median: 84.5;
range: 29–613)
98.1 U/l (SD: +/−41.7; median: 88.5;
range: 30–201)
45.5 U/l (SD: +/−21.9; median: 46; range: 18–72)
ALT 64.5 U/l (SD: +/−40.6; median: 59;
range: 10–155)
59.6 U/l (SD: +/−30.2; median: 57.5;
range: 16–124)
20.2 U/l (SD: +/−10.1; median: 21; range: 4–35)
GGT 158.2 U/l (SD: +/− 194.2; median: 97;
range: (5–104)
158.2 U/l (SD: +/−108.7; median: 124;
range: 29–515)
65.3 U/l (SD: +/−28.4; median: 66;
range: 22–102)
Table 3 Frequency of NTBC side effects (100%= 158
patients)
NTBC side effect Patients (n) %
Thrombocytopenia 8 5.0
Leukopenia 3 1.8
Eye pain 10 6.3
Eye itching 9 5.6
Conjunctivitis 3 1.8
Ceratitis 3 1.8
Corneal crystals 5 3.1
Epithelial abnormalities 1 0.63
Cognitive impairment 1 0.63
Behavioural disorder 1 0.63
Constipation 1 0.63
Myoclonia 1 0.63
Eczema 3 1.8
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Acute liver failure seems to be a very rare complication
(5/148 patients) in late diagnosed and treated patients
(>6 months of age). Clinical sequelae were rarely observed
in patients treated early (<1 month of age) with NTBC
(Figure 4). The rate of clinical complications critically de-
pends on the age at start of treatment (Table 4). 1/148
treated patient died because of failure of the transplanted
liver; the patient was diagnosed and treated at the age of
5 years. 2/148 patients (at diagnosis: 8 months and
10 months of age) died from HCC (metastasis).
Therapeutic monitoring
The amino acid profile was monitored by 95% of cen-
tres. 10% of centres used urine and 48% dried blood
spots, 42% plasma. The maximal acceptable plasma
level of tyrosine varied between 200–800 μmol/l (mean:
481.7 +/− 118 μmol/l).
SA was measured by all centres. Monitoring of SA was
performed in blood by 29% of centres, by 81% of centres
in urine and 62% of centres used dried blood spots. 86%
of centres stated that the target of SA should be below
detection limit. 14% of centres gave a target value for SA
levels in plasma below 0.1 μmol/l and in urine below
0.1 mmol/mol creatinine.
Urinary delta-aminolevulinate and metabolites were
measured in 10/21 centres.
Monitoring of NTBC plasma levels was performed in
76% of centres; 38% used dried blood spots; 76% of
Figure 4 The frequency of complications depends on the age at start of NTBC-treatment. a-g: Age at initiation of NTBC treatment
and frequency of complications: The most common complications like liver disease, HCC,renal dysfunction, rickets and necessity of liver
transplantation are shown. *significant difference (p <0.05) vs < 1 month. n: < 1 m =37 patients; 1-6 m =45 patients; 7-12 m =20
patients; >13 m =46 patients.
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centres measured NTBC in serum. 33% of centres used
standardized sampling with trough levels of 30–50 μmol/l
(7 centres) and peak levels of 50–100 μmol/l (6 centres)
and 29% preferred random sampling with target levels be-
tween 20–80 μmol/l.
Follow-up
All centres performed regular blood count. 43% of cen-
tres assessed vitamin A and vitamin E, 57% of centres
measured vitamin D and vitamin B12 in their patients.
Folate was measured by 48% of centres and micronutri-
ents by 62% of centres.
Biochemical parameters like methylmalonic acid in urine
or in blood, homocysteine, IGF1, selenium, zinc, TSH,
parathyroid hormone, ferritin, CRP, bilirubin, electrolytes,
tubular function, carnitine and prealbumin were not regu-
larly determined in all centres.
Liver assessment
PTT was measured by 91% of centres; PT by 76%. AST/
ALT levels were monitored by 76% of centres whereas
gamma GT was measured by 95% of centres. 90% of
centres included measurement of albumin in their rou-
tine procedures and 95% of centres stated to measure al-
kaline phosphatase. All centres monitored AFP levels
and regularly performed ultrasound of the liver. 76% of
centres stated to perform MRI in addition. 5% of centres
used CT for liver imaging. The frequency of liver im-
aging varied from every 3 months to once a year. 62%
recommended yearly liver imaging.
Table 4 Age at NTBC-start and sequelae: odds ratio of patients diagnosed and treated beyond the perinatal period
compared to those treated below the age of 1 month (OR = Odds ratio; 95% LCI = lower limit of 95% confidence interval;
UCI = upper limit of 95% confidence interval)
Complications 1-6 m n=45 patients 7-12 m n= 20 patients >12 m n= 46 patients
OR LCI 95% UCI 95% OR LCI 95% UCI 95% OR LCI 95% UCI 95%
LTx 2.5 0.2 25.8 4 0.3 47.1 12.7 1.5 103
acute liver failure 2.5 0.1 63.9 15 0.7 306.4 2.4 0.09 62.4
Carcinoma 2.5 0.2 25.8 6.3 0.6 65.6 12.7 1.5 103
Cirrhosis 8.1 0.4 156.1 41.6 2.2 779.9 40.5 2.3 704.1
hepatomegaly 3.3 0.9 11.3 4.4 1.1 17.7 3.9 1.1 13.3
Rickets 4.3 0.2 92.6 10.1 0.5 222.1 19 1.1 338.3
renal dysfunction 1.7 0.2 9.8 5.8 1.0 33.4 5.5 1.1 26.6
renal tubular dysfunction 1.2 0.1 7.9 1.9 0.2 14.9 4.3 0.8 21.6
nephromegaly 0.8 0.1 6 3.0 0.4 20.2 2.6 0.4 13.8
nephrocalcinosis 4.3 0.2 92.6 5.7 0.2 148.3 2.5 0.09 62.5
impaired growth 2,5 0.1 63.9 1.8 0.03 95.6 2.5 0.09 62.5
Adipositas 2.5 0.1 63.9 1.8 0.03 95.6 2.5 0.09 62.5
neurological concomitant disease 1.4 0.3 6.3 0.5 0.05 6.1 0.2 0.02 2.5
neurological crises 0.2 0.02 2.5 0.5 0.05 6.1 0.2 0.02 2.5
Epilepsy/convulsion 0.8 0.1 3.4 0.9 0.1 5.5 0.1 0.02 1.7
ADS, behavioural disorders 1.4 0.3 6.3 1.2 0.1 8.2 0.5 0.08 3.2
learning/language difficulties 0.8 0.05 13.5 0.5 0.02 15.2 0.2 0.01 6.6
Impaired psychomotor development 0.7 0.2 2.3 1.5 0.4 5.34 0.7 0.2 2.27
Death 0.8 0.01 42.5 15 0.7 306.4 2.5 0.09 62.5
Figure 5 Differences in dietary treatment. Phe = Phenylalanine;
Tyr = Tyrosine.
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Renal evaluation
GFR and cystatin c were assessed by 5% of centres. Serum
urea, calcium and phosphate were measured by 95% of
centres. All centres stated to measure serum creatinine.
Renal ultrasound was performed by 85% of centres. 67%
of centres indicated to carry out renal imaging once a year.
Some centres performed renal imaging every 3 months or
every 6 months. In 1 centre MRI of kidneys was regularly
carried out.
Psychomotor assessment
Assessment was performed by 14 out of 21 centres
(65%), frequencies differed from once per year, every two
or three years to assessment according to individual needs
or age. Most centres performed evaluation once a year.
Neurological follow-up
Follow-up was done in all centres by clinical examin-
ation. The frequency varied from at least once a year to
maximal every 3 months. EEG was performed on a regu-
lar basis by 1/21 centres.
Cardiac follow-up
Cardiac follow-up was carried out by 14/21 centres.
Skeletal examination
12 out of 21 centres (57%) performed skeletal examin-
ation. 8 centres used x-ray in their patients and 8 centres
performed osteodensitometry.
Ophthalmological examination
Follow-up via slit lamp examination was done by 15/21
centres. In 11/15 centres (71%) a yearly examination
took place.
Other centers recommended eye examination every
6 months, twice a year, once after diagnosis or every
2 years, some order eye examination only when clinical
symptoms occur.
Refund of expenses
In almost all centres (20/21) patients received refund of
expenses for NTBC and tyrosine –free amino acid mix-
ture and in 10/21 centres patients obtained reimburse-
ment for protein-restricted diet.
Discussion
Data from 168 patients with Tyr 1 were included in our
study. This may seem a small number, however the total
number of patients treated with NTBC in Europe is less
than 400 (personal communication, Erik Brouwer, Swedish
Orphan Biovitrum). We observed considerable differences
among centres in Europe, Turkey and Israel regarding
diagnosis, treatment and monitoring of Tyr 1.
Diagnosis
In our study, patients who were diagnosed after the neo-
natal period and consequently received NTBC-treatment
later, had a 2-12-fold higher risk (depending on age at
start of therapy) of developing hepatocellular carcinoma
compared to patients treated as neonates. This is in line
with results from earlier smaller studies showing an in-
creased risk for hepatocellular carcinoma when NTBC
treatment was initiated at a later age [12,15,21]. Our
Table 5 Protein intake and age bands (g/kgBW per day)
Age bands Total protein intake
(mean +/−SD)
Intake via amino acid
mixture (mean +/−SD)
0-1 y 1.4 +/− 0.5 1.1 +/− 0.1
2-5 y 1.5 +/− 0.5 0.9 +/− 0.4
6-10 y 1.0 +/− 0.6 0.8 +/− 0.36
11-15 y 0.9 +/− 0.6 0.7 +/− 0.37
16-20 y 0.6 +/− 0.3 0.7 +/− 0.37
>20 y 0.5 +/− 0.2 0.8 +/− 0.15
Table 6 Clinical outcome and frequency of different
symptoms (mean age at onset and age range) in the
treated cohort (100%= 148 patients)
Outcome Patients %
Liver transplantation 18 12.2
Acute liver disease (12 months; SD: 9.2; range: 5–28) 5 3.4
Carcinoma (74.3 months; SD: 67; range: 6–216) 19 12.8
Cirrhosis (19.2 months; SD: 16.4; range: 3–72) 27 18.2
Hepatomegaly (26.2 months; SD: 16.4; range: 1–204) 29 19.6
Portal hypertension 1 0.7
Renal dysfunction (in general) 22 14.9
Renal tubular dysfunction (28.4 months; SD: 32.2;
range: 4–114)
16 10.8
Nephromegaly (23.3 months; SD: 20.6; range: 8–68) 13 8.8
Nephrocalcinosis (30 months; SD: 33.9; range: 6–54) 4 2.7
Nephrolithiasis, compensated renal failure 1 0.7
Rickets (28.3 months; SD: 21.4; range: 5–54) 13 8.8
Impaired growth 2 1.4
Adipositas 2 1.4
Cardiomyopathy (28 months) 1 0.7
Neurological concomitant diseases (55 months;
SD: 40.9; range: 7.1-96)
10 6.8
Neurological crisis (41.2 months; SD: 23.2; range: 9–60) 6 4.1
Epilepsy and convulsion 11 7.4
Hyperactivity, ADHS, behavioural disorders 12 8.1
Learning/language difficulties, dyslexia 2 1.4
Impaired psychomotor development
(29.4 months; SD: 29.3; range: 3–96)
30 20.3
Death 3 2.0
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results show that the risk for HCC is already increased
when treatment is initiated beyond the newborn period.
As patients were often asymptomatic in the first few
months of life and the initial clinical symptoms were
rather unspecific newborn screening is mandatory to
diagnose patients early in life. Tyrosine levels in blood
(spots) are an inappropriate screening parameter lacking
both sensitivity and specificity [22]. In contrast, SA in
dried blood is a specific and sensitive screening param-
eter which can be indirectly [23] or directly [22,24-29]
determined, additional measurement of tyrosine in dried
blood is optional.
Despite compelling evidence that NBS can prevent
liver carcinoma, still 43% of the participating centres do
not screen for Tyr 1. The majority of patients in our study
(132/168) were diagnosed by selective screening after
presentation of clinical symptoms.
Higher initial AFP levels in patients screened via NBS
compared to those who were diagnosed late are partly
due to age-dependency of AFP levels [30,31].
In line with previous studies, we could not find a clear
genotype-phenotype correlation [32] using two classifi-
cations described by Halvorsen 1990 and van Spronsen
1994, respectively [33,34]. Some mutations are population-
specific [35], nevertheless similar to Couce et al. [13] we
found IVS 6 -1(G > T) to be one of the most common mu-
tations, but IVS12 + 5G >A (c.1062 + 5G >A) was frequent
as well. Lack of genotype-phenotype correlation may partly
be due to genetic reversion, as mosaicisms in liver nodules
can be found and self –induced genetic corrections in liver
tissue may improve the clinical phenotype [36,37].
Implications for clinical practice
A delay in instituting NTBC-treatment beyond the neo-
natal period results in an increased risk for HCC (up to
12 fold in children older than 12 months). When SA is
used as a screening parameter, NBS for Tyr 1 fulfils the
criteria laid down by Wilson and Jungner [38]. In most
patients, there is latency until (irreversible) clinical symp-
toms occur, a specific and sensitive screening test exists,
efficient therapy is available and the test is acceptable for
the public. Our results underpin the importance and ne-
cessity of newborn screening using SA as a screening par-
ameter, tyrosine may be used as an additional parameter.
Mutation analysis is not essential for clinical manage-
ment but is useful for prenatal diagnosis and reproduct-
ive counselling.
Treatment and Monitoring of Therapy
The starting dose was 1–2 mg/kg BW per day in all cen-
tres. In younger patients with liver failure, a loading dose
of 2 mg/kg BW per day for 1 week was given. The initial
dose could be titrated down in most patients (even as
low as 0.3 mg/kg per day) without risking metabolic
control as judged by SA levels/excretion [39]. But it has
to be pointed out that levels of NTBC may fluctuate
during intercurrent illness (e.g. fever, infections), there-
fore very low levels should be avoided.
NTBC-treated FAH −/− knock-out mice developed
liver failure or died after complete withdrawal of NTBC
[40]. In this animal model, discontinuation and restart of
NTBC treatment favoured formation of liver tumours
while continuous low-dose NTBC treatment promoted
regeneration of liver lesions in these FAH−/− knock-out
mice (personal communication AV and JE). Whether
these findings can be transferred to clinical medicine is
not clear. Additionally, patients may develop neurological
crises in response to discontinuation of NTBC [41]. As
shown in Table 6 some (transient) symptoms (mainly liver
and kidney) may occur in the early phase after treatment
initiation.
In our survey, 2 daily doses were given on average.
Due to the long half-life of NTBC, once daily dosing may
be an option in older children to increase compliance.
Pharmacokinetics of NTBC in smaller children is still
unclear. The publication by Schlune et al. [42] advocating
once daily dosing sheds some indirect light on the pharma-
cokinetics of NTBC in children. Typical side effects of
NTBC were transient thrombocytopenia, leukopenia and
ocular symptoms which are comparable to data from
the post marketing survey (personal communication,
Erik Brouwer, Swedish Orphan Biovitrum). In our data
collection, only 8 patients had thrombocytopenia and 3
patients developed leukopenia. On average, patients with
side effects seem to have a higher range of NTBC values
compared to those with no side effects, however the sam-
ple size of patients with side effects was small; a statistical
analysis was not possible. Transient ocular symptoms
were reported in patients with poor dietary control. It was
previously reported that ocular symptoms were associated
with high tyrosine levels [43], whereas in another study
patients with high plasma tyrosine levels did not develop
any ocular symptoms [44].
In all centres, metabolic control was monitored using SA
concentration in dried blood and/or urine, the target
level is below detection limit
Not all centres monitored NTBC–levels in patients.
While metabolic control can be judged by SA levels/ex-
cretion in urine overdosing and compliance can only be
judged by measuring NTBC-levels. Monitoring of NTBC
plasma levels is therefore useful and permits individual
dosing. Thus, treatment costs and side effects can be
minimized without hampering metabolic control. The
target level of NTBC varied among centres. Target levels
are not well defined, in the literature, different target
levels of NTBC have been suggested [39,42,45-47].
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The centres unanimously used dietary treatment in Tyr
1. However, centres had different approaches concerning
dietary treatment and supplementation of micronutrients
and vitamins. Maximal acceptable plasma tyrosine levels
in the different centres ranged from 200–800 μM. As
some centres used plasma, while others used dried blood
this broad range may be partly due to using different sam-
pling material; Concentrations measured in dried blood
are about 1.4 times lower compared to plasma [39], unless
normalized to haemoglobin content [48]. Recently, diurnal
variation of phenylalanine in Tyr I patients has been de-
tected [49], the clinical significance for the outcome is
unknown. In our survey, frequency of tyrosine measure-
ments depended on age and biochemical stability.
Implications for clinical practice
Tyrosine restriction is recommended. It is not clear
whether protein restriction or calculation of tyrosine and
phenylalanine intake should be preferred. Judged by clin-
ical experience, we think that tyrosine and phenylalanine
calculation is justified in younger children during their
first 1–2 years of life and not necessary in older patients.
Regular intake of a tyrosine-free amino acid mixture di-
vided in 3 daily doses is essential to improve uptake of
amino acids. Micronutrients, vitamins and phenylalanine
should be supplied according to blood levels and/or diet-
ary protocols.
Based on discussion and experience, the workshop
group agreed on a target tyrosine level in plasma below
400 μM which is regarded as both safe and feasible. This
was also recommended by other groups [2,18].
Continuous NTBC-treatment at a starting dose of 1–
2 mg/kg per day is necessary to avoid sequelae. We rec-
ommend adjusting the individual NTBC dose according
to NTBC- and SA- levels in order to minimize side ef-
fects and costs. Based on a review of the literature and
personal experience, the workshop group recommends a
NTBC plasma level between 20 and 40 μM at random
sampling. Once daily dosing may be an option in older
children to improve compliance. In younger children
pharmacokinetics of NTBC are not yet clear twice daily
dosing seems to be adequate in this group. Random
sampling is possible as NTBC has a long half-life of 54 h
[50]. NTBC levels in dried blood spots are 1.4-1.6 times
lower compared to plasma [39] unless samples are nor-
malized to haemoglobin content [48].
Prospective data related to outcome are necessary to
underpin our opinions regarding target values for tyro-
sine and NTBC as well as a correlation between NTBC
levels and side effects.
Liver transplantation
In our study, liver transplantation was the therapy of
choice in patients with hepatocellular carcinoma.
Further indications were failure to respond to NTBC
(therapy-resistant liver failure with insufficient improve-
ment despite treatment with a NTBC-loading dose of
2 mg/kg per day for one week), chronic liver disease or
poor quality of life due to dietary restriction and frequency
of blood sampling which is comparable to previous find-
ings [51].
Stabilization by NTBC-treatment before liver trans-
plantation improved the outcome. Patients with a high
post-transplant tyrosine plasma level or urinary SA excre-
tion may benefit from protein restriction and low-dose
NTBC treatment [52,53]. In our retrospective study, 6
patients from 3 different centres received NTBC and 4 of
them were treated with a protein restricted diet after
transplantation with a good outcome.
Implications for clinical practice
Liver transplantation is indicated in hepatocellular car-
cinoma and NTBC-resistance. Whether post-transplant
NTBC and dietary treatment in patients excreting SA in
urine after transplantation is necessary should be exam-
ined in future studies.
Monitoring and follow-up
The frequency of follow-up procedures, techniques and
scope of laboratory examinations were heterogeneous
among centres. Comparable heterogeneities of follow-
up procedures have been reported by a French–Belgian
study group in a local study [16].
Dried blood spots are convenient for home monitor-
ing, especially useful in remote areas for simultaneous
measurement of succinylacetone, tyrosine, phenylalanine
and NTBC [39,48].
Ultrasound of the liver was regularly performed, the
frequency of imaging varied from every 3 months to
once a year. Ultrasound of the liver in experienced hands
seems to be appropriate for follow-up. MRI was per-
formed in most centres when malignancy was suspected.
Occasionally, nodules are present before initiation of
NTBC-treatment but regress on repeated imaging fol-
lowing treatment [18].
In our study, Fanconi-syndrome-like tubulopathy and
hypophosphataemic rickets were the most common
renal manifestations of Tyr 1. The tubulopathy associ-
ated with Tyr 1 was previously reported to be reversible
[54], however progressive tubular dysfunction can
lead to glomerular dysfunction [53]. According to the
group’s experience, urinary testing should be performed
once a year or until normal values are obtained using
protein, glucose, beta1-albumin, alfa1-microglobuline
and albumin.
In our case-series, minor cardiac dysfunction was only
observed in one single patient who presented with minor
cardiomyopathy. Cardiomyopathy in treated Tyr 1 is a
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rare complication mostly with a favourable outcome
[55-57], cardiac tests are only necessary when clinical
symptoms occur.
Half of the centres performed skeletal examination (x-
ray or osteodensitometry). In our study, bone symptoms
like rickets were rare, corneal crystals with clinical symp-
toms were only found in 8 patients. Hence skeletal and
ophthalmologic tests are only necessary when clinical
symptoms exist.
Well-known neurological features of Tyr 1 are por-
phyria-like crises and peripheral neuropathy. These
were rare in our cohort. Only recently, cognitive deficits
were described in some Tyr 1-patients treated with
NTBC [5-8,11]. In our study, 20% of patients had psy-
chomotor impairment and 17 patients (11.5%) required
special education. However, regular psychomotor and
intelligence testing is rarely performed (14/21 centres).
More widespread testing is warranted in order to better
characterize these problems and offer specific support.
The mechanisms leading to psychomotor impairment
are still unclear. Elevated levels of tyrosine, other toxic
metabolites and NTBC have been discussed to play a
role. Tyrosine may compete with the transport of other
amino acids to the brain. The synthesis of neurotrans-
mitters might be altered by NTBC-related hypertyrosi-
naemia [5].
Implications for clinical practice
The workshop group recommends ultrasound of the liver
every 6 months and monitoring of AFP levels every 3–6
months. Contrast-enhanced ultrasound is more sensitive.
When malignancy is suspected, MRI of the liver with add-
itional measurement of AFP blood levels is recommended
as has been suggested before [58]. Based on clinical ex-
perience, the group judges MRI to be more sensitive in de-
tecting tumours compared to ultrasound of the liver.
Regular monitoring of tubular function is recommended.
Cardiac follow-up, osteodensitometry and slit lamp
examination of the eyes is not considered obligatory but
should be performed according to clinical and biochem-
ical pathology.
A regular psychomotor assessment is highly recom-
mended in order to support affected children by special
education. Further studies are necessary to elucidate the
underlying pathophysiology.
Unmet needs
Financial support is an important issue for access to an
optimal treatment; in almost all centres, patients received
refund of expenses for NTBC and tyrosine-free amino
acid mixture. But only patients in half of the participating
centres obtained reimbursement for a protein-restricted
diet which might affect the access and adherence to
treatment.
Implications for clinical practice
Costs for neonatal screening and treatment have to be
born by the government or health insurance companies to
allow early diagnosis and access to adequate treatment.
Conclusions
We present data from a retrospective, cross sectional
study including a substantial number of 168 patients
with Tyr 1.
Our results underpin the urgent need for NBS in Tyr
1 using SA as a screening parameter. The risk for devel-
oping HCC in the untreated patient increases during the
first months of life by a factor of 13 compared to new-
borns. Treatment consists of a protein reduced diet and
NTBC. Once daily dosing may be an option in older
children to increase compliance. NTBC should be indi-
vidually dosed to minimize both side effects and costs.
Target levels suggested by our group are 20–40 μM for
Table 7 Summary of clinical practice recommendations and issues to be addressed in future (prospective) studies
Clinical practice recommendation Issues to be addressed in future studies
Diagnosis •NBS via SA to avoid sequelae including HCC
Treatment & Monitoring •NTBC & diet •Calculation Tyr & Phe vs protein restriction
•NTBC-level 20-40 μM •NTBC-target level
•Tyr-level < 400 μM •Tyr-target level
•SA below detection limit •SA target level
•Contrast enhanced ultrasound & AFP •Correlation NTB-levels & side effects
•Liver & Kidney function •NTBC- pharmacokinetics in children
Liver transplantation •HCC •NTBC & diet if SA-elevation post transplant
•Therapy resistance
Outcome
•Psychomotor/neurocognitive assessment
•Pathophysiology of neurological damage and risk factors
•Definition of adequate test battery
Reimbursement •Diagnosis & Treatment & Monitoring
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NTBC and 400 μM for tyrosine in plasma. Further pro-
spective studies including outcome parameters are
needed for confirmation.
For monitoring liver carcinoma, our group judged (con-
trast-enhanced) ultrasound in combination with tumour
markers appropriate as a routine procedure, MRI should
only be performed if malignancy is expected. Hepatic and
renal function has to be assessed regularly. Evaluation of
bone, ocular and cardiac function is only recommended in
the presence of clinical symptoms. Neurocognitive deficits
have been frequently observed in our cohort. It is not clear
whether these are symptoms of the disease or side-effects
of medication. Regular assessment of psychomotor and
cognitive function is recommended. Prospective studies
are required to further characterise neurocognitive out-
come in Tyr 1.
Clinical implications deducted from our findings and
unsolved issues arising from our study and workshop
discussion are summarized in Table 7.
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